Tags

Type your tag names separated by a space and hit enter

Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Gynecol Oncol. 2013 Sep; 130(3):609-14.GO

Abstract

BACKGROUND

The objective of this study is to analyze the distribution, clinicopathological features, relative survival rate and excess risk of death among females diagnosed with invasive breast cancer and classified by molecular subtype from ten Spanish cancer registries.

METHOD

Three thousand four hundred and eighty incident cases of women - mostly diagnosed in 2005 - were classified into five molecular subtypes according to immunohistochemical status of hormonal receptors and HER2 (human epidermal growth factor receptor 2): estrogen receptor (ER) and/or progesterone receptor (PR)+ and HER2-, ER+ and/or PR+ and HER2+, HER2-overexpressed (ER-, PR- and HER2+), triple negative (ER, PR and HER2-) and unclassified (hormonal receptor or/and HER2 unknown). Relative survival rates at 1, 3 and 5years and relative excess risks (RER) of death adjusting for molecular subtype, age, stage and histological grade were estimated.

RESULTS

Marked differences in clinicopathological characteristics and relative survival rate were observed between molecular subtypes. Compared with women with ER+ and/or PR+ and HER2-, ER+ and/or PR+ and HER2+ cases had an RER of 1.00 (95% CI: 0.66 to 1.52) after adjusting for age, stage and histological grade, whereas HER2-overexpressed, triple negative and women with unclassified subtypes presented an RER of 1.72 (95% CI: 1.15 to 2.57), 3.16 (95% CI: 2.26 to 4.41) and 2.55 (95% CI: 1.96 to 3.32), respectively.

CONCLUSION

The prognostic value of molecular subtype persists when adjusting for age, stage and histological grade. Hormone receptor-positive tumors were associated with a better prognosis when compared with HER2-overexpressed and triple negative subtypes. Further research is required to improve triple negative prognosis.

Authors+Show Affiliations

Epidemiology Unit and Girona Cancer Registry, Girona, Spain. mpuig.icogirona@gmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23747837

Citation

Puig-Vives, M, et al. "Distribution and Prognosis of Molecular Breast Cancer Subtypes Defined By Immunohistochemical Biomarkers in a Spanish Population-based Study." Gynecologic Oncology, vol. 130, no. 3, 2013, pp. 609-14.
Puig-Vives M, Sánchez MJ, Sánchez-Cantalejo J, et al. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. Gynecol Oncol. 2013;130(3):609-14.
Puig-Vives, M., Sánchez, M. J., Sánchez-Cantalejo, J., Torrella-Ramos, A., Martos, C., Ardanaz, E., Chirlaque, M. D., Perucha, J., Díaz, J. M., Mateos, A., Machón, M., & Marcos-Gragera, R. (2013). Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. Gynecologic Oncology, 130(3), 609-14. https://doi.org/10.1016/j.ygyno.2013.05.039
Puig-Vives M, et al. Distribution and Prognosis of Molecular Breast Cancer Subtypes Defined By Immunohistochemical Biomarkers in a Spanish Population-based Study. Gynecol Oncol. 2013;130(3):609-14. PubMed PMID: 23747837.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. AU - Puig-Vives,M, AU - Sánchez,M J, AU - Sánchez-Cantalejo,J, AU - Torrella-Ramos,A, AU - Martos,C, AU - Ardanaz,E, AU - Chirlaque,M D, AU - Perucha,J, AU - Díaz,J M, AU - Mateos,A, AU - Machón,M, AU - Marcos-Gragera,R, Y1 - 2013/06/06/ PY - 2013/04/10/received PY - 2013/05/28/revised PY - 2013/05/30/accepted PY - 2013/6/11/entrez PY - 2013/6/12/pubmed PY - 2013/11/13/medline KW - Breast cancer KW - HER2 KW - Hormonal receptor KW - Molecular subtype KW - Relative survival SP - 609 EP - 14 JF - Gynecologic oncology JO - Gynecol Oncol VL - 130 IS - 3 N2 - BACKGROUND: The objective of this study is to analyze the distribution, clinicopathological features, relative survival rate and excess risk of death among females diagnosed with invasive breast cancer and classified by molecular subtype from ten Spanish cancer registries. METHOD: Three thousand four hundred and eighty incident cases of women - mostly diagnosed in 2005 - were classified into five molecular subtypes according to immunohistochemical status of hormonal receptors and HER2 (human epidermal growth factor receptor 2): estrogen receptor (ER) and/or progesterone receptor (PR)+ and HER2-, ER+ and/or PR+ and HER2+, HER2-overexpressed (ER-, PR- and HER2+), triple negative (ER, PR and HER2-) and unclassified (hormonal receptor or/and HER2 unknown). Relative survival rates at 1, 3 and 5years and relative excess risks (RER) of death adjusting for molecular subtype, age, stage and histological grade were estimated. RESULTS: Marked differences in clinicopathological characteristics and relative survival rate were observed between molecular subtypes. Compared with women with ER+ and/or PR+ and HER2-, ER+ and/or PR+ and HER2+ cases had an RER of 1.00 (95% CI: 0.66 to 1.52) after adjusting for age, stage and histological grade, whereas HER2-overexpressed, triple negative and women with unclassified subtypes presented an RER of 1.72 (95% CI: 1.15 to 2.57), 3.16 (95% CI: 2.26 to 4.41) and 2.55 (95% CI: 1.96 to 3.32), respectively. CONCLUSION: The prognostic value of molecular subtype persists when adjusting for age, stage and histological grade. Hormone receptor-positive tumors were associated with a better prognosis when compared with HER2-overexpressed and triple negative subtypes. Further research is required to improve triple negative prognosis. SN - 1095-6859 UR - https://www.unboundmedicine.com/medline/citation/23747837/Distribution_and_prognosis_of_molecular_breast_cancer_subtypes_defined_by_immunohistochemical_biomarkers_in_a_Spanish_population_based_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-8258(13)00828-7 DB - PRIME DP - Unbound Medicine ER -